###begin article-title 0
###xml 112 117 <span type="species:ncbi:9606">women</span>
Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2</italic>
Single nucleotide polymorphism (SNP) 309 resulting in a T or G allele in the promoter of MDM2, the negative regulator of p53, has been suggested to affect cancer predisposition and age of onset, primarily in females. However, findings have been inconsistent in various cancers, and ethnicity appears to be a critical factor influencing the effects of the SNP on cancer risk. An increasing trend has been observed in the prevalence of lung cancers in non-smokers, especially females, though the underlying genetic basis is unclear.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
We therefore examined the role of the SNPs in the p53 pathway (p53 codon 72 and MDM2 SNP309) on lung cancer risk and prognosis of a life-time non-smoking female Chinese population, in a hospital-based case-control study of 123 cases and 159 age-matched controls, by PCR analysis.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 315 319 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
Our findings reveal that the risk of lung cancer among individuals with the MDM2 SNP309 TT genotype was 2.1 (95% CI 1.01-4.36) relative to the GG genotype, contrary to initial expectations that the GG genotype with elevated MDM2 levels will increase cancer risk. Those who had this genotype in combination with the p53 Pro allele had a risk of 2.5 (95% CI 1.2-5.0). There was however no effect of either polymorphism on age at diagnosis of lung cancer or on overall survival.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
The results thus demonstrate that the MDM2 SNP309 TT rather than the GG genotype is associated with increased risk of lung cancer in this population, suggesting that other mechanisms independent of increased MDM2 levels can influence cancer susceptibility.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 723 724 723 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 725 726 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 864 865 864 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 313 319 <span type="species:ncbi:10090">murine</span>
The TP53 tumour suppressor pathway plays a critical role in cell cycle regulation and apoptosis in many cancers, including lung carcinomas [1], and variation in the genes that regulate this pathway may exert an important influence on tumour development, and hence, cancer risk. Recent interest has focused on the murine double minute-2 protein (MDM2), a nuclear phospoprotein that inhibits p53 activity by promoting its degradation [2]. A single nucleotide polymorphism (SNP309) in the MDM2 promoter has been found to influence transcription of this gene via a greater affinity for the SP1 transcription factor, and hence, individuals with the GG genotype have higher MDM2 levels leading to attenuation of the p53 pathway [3,4]. This has been especially so in the case of females, due to the involvement of the MDM2 SNP in the estrogen receptor signaling pathway [3].
###end p 10
###begin p 11
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 916 921 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1748 1750 1748 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1778 1780 1778 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1781 1783 1781 1783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
Several epidemiologic studies have evaluated this association with varying results. No overall association between MDM2 SNP309 and lung cancer risk was observed in recent studies in a European [5], North American [6,7] and two Asian [8,9] populations. However, the GG genotype was observed to increase risk in a study in China [10], Norway [11] and among non-Hispanic Whites in the US [12]. In some cases, even though there was no overall association noted with the MDM2 SNP309 and cancer susceptibility, substratification of groups led to some association. For example, an increased risk was correlated with the GG genotype only in the adenocarcinomas, but not in the small cell, squamous cell or non-small cell lung cancers (NSCLCs), or when all lung cancer subtypes were grouped [9]. Other studies pointed to an interaction with smoking status - although no association was found between all lung cancers and the MDM2 SNP309, there was an elevated risk of cancer susceptibility in smokers compared to non-smokers in the same study [10]. Conversely, one study found that the risk of lung cancer was higher among individuals with the TT genotype - on stratification, this association was restricted to males and to smokers [12]. A meta-analysis of seven studies concluded that the GG genotype conferred a small but significant increased risk (summary odds ratio [OR] 1.27; 95% confidence interval [CI] 1.12-1.44) [13]. Because of the capacity of the polymorphism to enhance the inhibitory action of MDM2 on the p53 pathway, investigators have hypothesized that the GG genotype would also negatively influence prognosis in lung cancer. To date, two studies have demonstrated that the GG genotype is associated with a lower level of p53 expression [14] and with poorer survival [14,15].
###end p 11
###begin p 12
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 522 524 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
A polymorphism at codon 72 of the p53 gene resulting in an arginine-to-proline (Arg/Pro respectively) substitution has also been shown to be varyingly associated with cancer predisposition, possibly due to differences in ethnicity and in background risk due to smoking [16-18]. A meta-analysis of 13 epidemiologic studies which examined this association reported that the summary odds ratio of lung cancer associated with the Pro/Pro genotype was 1.18 (95% CI 0.99-1.41), and was 1.02 (95% CI 0.86-1.20) for Pro-carriers [19]. The Pro/Pro genotype has also been associated with poorer prognosis and less favorable clinical outcome in lung cancer patients [14,20,21]. Moreover, significantly higher or a lower prevalence of p53 gene mutations have been noted in lung cancers among carriers of the Pro allele in the Polish [22] or a Norwegian population [23], respectively. These data highlight that ethnicity and other factors may have an impact on p53 functionality, with respect to the SNP and mutational status.
###end p 12
###begin p 13
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 559 564 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 209 212 <span type="species:ncbi:9606">men</span>
###xml 500 505 <span type="species:ncbi:9606">women</span>
The influence of gender and ethnic differences on genetic determinants of lung cancer is increasingly being recognized. Smoking accounts for the overwhelming majority of cases in Western populations and among men, but lung cancer among non-smokers is now known to be a distinct clinico-pathologic entity that is as yet poorly understood [24,25]. We therefore sought to examine if MDM2, through its role in the p53 pathway, is associated with risk and prognosis of lung cancer among Singapore Chinese women, a primarily non-smoking population. In addition, as MDM2 SNP309 status has been demonstrated to affect the overall age of onset of various cancers, with differential effects in different populations [4,26], we have explored its effects in this unique population.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Study population
###end title 15
###begin p 16
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 94 99 <span type="species:ncbi:9606">women</span>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">Patients</span>
###xml 496 508 <span type="species:ncbi:9606">participants</span>
###xml 593 605 <span type="species:ncbi:9606">participants</span>
Participants were drawn from a hospital-based case-control study on lung cancer among Chinese women in Singapore [27]. Incident cases were primary lung cancers diagnosed at any one of three major hospitals in the country over the study period, and controls were patients admitted to the same hospitals, frequency-matched by age. Patients admitted for malignant or chronic respiratory conditions (chronic bronchitis, emphysema and chronic asthma) were not eligible to participate as controls. All participants provided written consent. Within this study population, a consecutive sub-sample of participants were asked, and consented to provide a blood specimen for genetic analysis. Of these, 126 cases (95.2% of which were pathologically confirmed) and 162 controls were never smokers and form the basis for the current report. The study was approved by the Ethics Committee of the National Cancer Centre and the Institutional Review Board of the National University of Singapore.
###end p 16
###begin p 17
###xml 71 77 <span type="species:ncbi:9606">person</span>
###xml 238 245 <span type="species:ncbi:4097">tobacco</span>
Demographic, smoking and other relevant information was obtained by in-person interview with a trained nurse. A lifetime non-smoker was defined by a negative response to the question "Have you ever smoked a cigarette or any other form of tobacco, at least once a day for one year?"
###end p 17
###begin p 18
Genomic DNA was prepared from peripheral blood using the standard proteinase K-phenol-chloroform procedure and DNA was stored at -30degreesC till analysis.
###end p 18
###begin title 19
Laboratory analysis
###end title 19
###begin p 20
###xml 285 289 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 491 497 491 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BstUI </italic>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
Genotyping was performed independently at the Department of Community, Occupational and Family Medicine, National University of Singapore, and at the Laboratory of Molecular Carcinogenesis, National Cancer Centre. Genomic DNA from peripheral blood samples was used for PCR analysis of p53 using the following primers: Forward: 5'-GAAGACCCAGGTCCAGATGA-3' and Reverse: 5'-ACTGACCGTGCAAGTCACAG-3', this gave rise to a 216 bp product, followed by BtgI digestion. The p53 Pro allele has a unique BstUI site that is absent in the Arg allele, resulting in bands of different sizes as follow: 50 bp, 166 bp (Pro/Pro), 216 bp (Arg/Arg) and 50 bp, 166 bp, 216 bp (Pro/Arg). Likewise, MDM2 promoter SNP309 was amplified as a 194 bp product using the following primers: Forward: 5'-CGGGAGTTCAGGGTAAAGG-3' and Reverse: 5'-TCGGAACGTGTCTGAACTTG-3'. Genotyping was then performed by digestion using restriction enzyme MspAI. The MDM2 promoter SNP309 G allele has a unique MspAI site that is absent in the T allele resulting in bands of different sizes as follows: 49 bp, 145 bp (G/G), 194 bp (T/T), 49 bp, 145 bp, 194 bp (G/T). MDM2 status was also confirmed by sequencing reactions using the following primers: Forward: 5'-CGGGAGTTCAGGGTAAAGGT-3' and Reverse: 5'-AGCAAGTCGGTGCTTACCTG-3', as described [26].
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 281 293 <span type="species:ncbi:9606">participants</span>
We used unconditional logistic regression to compute adjusted odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for the association between lung cancer risk and MDM2 SNP309 and p53 codon 72 genotypes. ORs were adjusted for age (in years) and birthplace. All participants were female, never smokers and ethnic Chinese.
###end p 22
###begin p 23
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
The Kruskal-Wallis test was carried out to evaluate the differences in the age of onset of cancer among patients with different genotypes, while Fisher's exact test was used to test the equivalence of distribution of cancer stage among patients with different genotypes. The Logrank test was performed to examine the differences between Kaplan-Meier-estimated overall survival among patients with different genotypes. Analyses were performed using STATA version 9.0 (Strata Corporation, College Station, TX USA) and SPSS for Windows version 15.0 (SPSS Inc., Chicago, IL).
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 347 354 <span type="species:ncbi:4097">tobacco</span>
Table 1 provides a description of relevant demographic and other background characteristics of cases and controls. They were similar in respect of age, years of education, and cases were more likely to have been born outside of Singapore than controls. They were also less likely to consume fruit and vegetables, or to be exposed to environmental tobacco smoke at home. Approximately three-quarters of the cases were adenocarcinomas.
###end p 25
###begin p 26
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
Distribution of selected characteristics among cases and controls1
###end p 26
###begin p 27
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sup>
###xml 6 18 <span type="species:ncbi:9606">participants</span>
###xml 31 36 <span type="species:ncbi:9606">women</span>
1 All participants are Chinese women, cases and controls frequency-matched for age. A total of 126 cases and 162 controls were eligible, of which 123 and 159, respectively, were successfully genotyped.
###end p 27
###begin p 28
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
2 Refers to age at diagnosis (cases) and age at interview (controls)
###end p 28
###begin p 29
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
A total of 123 (97.6%) cases and 159 (98.1%) controls were successfully genotyped for both polymorphisms. Genotype frequencies were comparable with the published literature and in keeping with the lower prevalence of the T allele reported in Asian, relative to Caucasian, populations [7,8,10-12]. The distribution of genotype frequencies conformed to that expected under the Hardy-Weinberg equilibrium for both MDM2 SNP309 (p = 0.62) and TP53 codon 72 (p = 0.19).
###end p 29
###begin title 30
MDM2 SNP309 TT genotype increases lung cancer risk
###end title 30
###begin p 31
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
Risk of lung cancer was higher among individuals with the MDM2 SNP309 TT genotype relative to the GG genotype (OR 2.10, 95% CI 1.01-4.36) (Table 2). Heterozygotes showed an intermediate risk (OR 1.42, 95% CI 0.80-2.52).
###end p 31
###begin p 32
Risk of lung cancer in relation to MDM2 SNP309 and p53 codon 72 polymorphisms
###end p 32
###begin p 33
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sup>
###xml 131 136 <span type="species:ncbi:9606">women</span>
1 Adjusted for age in years and birthplace (China-born, Singapore/Malaysia-born). All individuals were lifetime non-smoker Chinese women.
###end p 33
###begin p 34
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
2 P (interaction) = 0.06
###end p 34
###begin p 35
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
Analysis of the p53 codon 72 SNP revealed that the presence of the p53 Pro allele was associated with a small but non-significant increase in risk: odds ratios for Arg/Pro and Pro/Pro genotypes were 1.21 (95% CI 0.67-2.17) and 1.44 (95% CI 0.70-3.00), respectively (Table 2).
###end p 35
###begin p 36
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
We next evaluated if the effect of MDM2 SNP was modified by p53 codon 72 status. The TT genotype conferred an elevated risk (OR 2.42, 95% CI 1.16-5.03) only among codon 72 Pro allele carriers (Table 2). However, the interaction was not statistically significant (p = 0.06). A similar magnitude of risk (OR 2.47, 95% CI 1.21-5.03) (data not shown) was conferred by the TT, Arg/Pro, Pro/Pro genotypes in combination, relative to the GG, Arg/Arg genotypes.
###end p 36
###begin p 37
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
Taken together, the data indicate that the TT genotype of MDM2 SNP309 is associated with increased lung cancer risk.
###end p 37
###begin title 38
p53 codon 72 polymorphism and MDM2 SNP309 status does not influence the age of diagnosis of lung cancer
###end title 38
###begin p 39
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 699 703 699 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
Kruskal-Wallis analysis indicated no association of the p53 codon 72 genotypes with age of onset in the study population (p = 0.557); 50% of the population were diagnosed between the ages of 60 and 63, regardless of the genotypes (Figure 1A), and the median age of onset for the Arg/Arg, Arg/Pro and Pro/Pro groups were found to be 64.5, 60.0 and 63.0, respectively. Similar analysis of the effect of the various MDM2 SNP309 genotypes also revealed no association between them and the age of onset of lung cancer (p = 0.338) (Figure 1B). The median age of onset for the T/T, T/G and G/G groups were found to be 59.0, 65.0 and 63.5, respectively (Figure 1B). Combined analysis of the effects of both p53 and MDM2 alleles also did not reveal any significant differences in the age of onset of the disease (p = 0.718)(data not shown).
###end p 39
###begin p 40
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 SNP309 </italic>
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 0 110 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>MDM2 SNP309 </italic>and <italic>p53 </italic>codon 72 polymorphism do not affect onset-age of lung cancer in female non-smoker patients</bold>
###xml 112 115 112 115 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A-B</bold>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 270 271 270 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 277 289 277 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 SNP309 </italic>
###xml 290 291 290 291 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
MDM2 SNP309 and p53 codon 72 polymorphism do not affect onset-age of lung cancer in female non-smoker patients. A-B. The cumulative incidence of cancer cases in the population was plotted as a function of age of onset of lung cancer, comparing the various p53 codon 72 (A) and MDM2 SNP309 (B) genotypes. No significant differences were noted with respective to both the different p53 and MDM2 genotypes. n = 21 for Arg/Arg, n = 16 for Pro/Pro and n = 47 for Arg/Pro and n = 22 for T/T, n = 19 for G/G and n = 54 for G/T.
###end p 40
###begin title 41
Overall survival is not influenced by p53 codon 72 polymorphism and MDM2 SNP309 SNP
###end title 41
###begin p 42
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2A</xref>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2A</xref>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2B</xref>
###xml 653 658 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 793 795 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2B</xref>
###xml 3 11 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
97 patients with survival data available were included in the survival analysis. The median follow-up time was 10.1 months. Analysis of overall survival revealed no statistically significant differences with respect to the various p53 genotypes (p = 0.263) (Figure 2A). The median survival for patients with Arg/Arg, Arg/Pro and Pro/Pro p53 genotypes were 5.47 (CI 95% 3.17-10.23), 10.87 (CI 95% 7.53-18.70) and 8.93 (CI 95% 4.33-11.63) months, respectively (Figure 2A). Similarly, no significant differences were observed with respect to the various MDM2 genotypes and overall survival (p = 0.267) (Figure 2B), and the median survivals for the various MDM2 SNP309 alleles were 11.17 (CI 95% 3.60-33.80) (T/T), 10.10 (CI 95% 5.47-11.90) (T/G) and 9.57 (CI 95% 5.17-18.70) (G/G) months (Figure 2B).
###end p 42
###begin p 43
###xml 0 124 0 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Polymorphic status of p53 codon 72 or MDM2 SNP309 does not affect overall survival of female non-smoker lung cancer patients</bold>
###xml 126 129 126 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A-B</bold>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Polymorphic status of p53 codon 72 or MDM2 SNP309 does not affect overall survival of female non-smoker lung cancer patients. A-B. Kaplan-Meier overall survival curves for all patients with different p53 (A) or MDM2 (B) genotypes. No significant differences were noted with respective to the different MDM2 or p53 genotypes alone or in combination. n = 21 for Arg/Arg, n = 16 for Pro/Pro and n = 47 for Arg/Pro and n = 22 for T/T, n = 19 for G/G and n = 54 for G/T.
###end p 43
###begin p 44
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
Combined analysis of the effects of both p53 and MDM2 polymorphisms on overall survival also did not reveal any significant differences among the nine different genotypes (p = 0.367) (data not shown).
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 332 336 332 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 126 131 <span type="species:ncbi:9606">women</span>
In summary, we show here that the MDM2 SNP309 TT genotype is associated with a higher risk of lung cancer among never smoking women in the Chinese population. The presence of the p53 codon 72 Pro allele did not lead to a statistically significant interaction or materially affect the magnitude of this risk. Neither of the MDM2 nor p53 polymorphisms evaluated showed any impact on survival or age of onset of lung cancer in this population.
###end p 46
###begin p 47
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 431 436 431 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 575 579 575 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53 </italic>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1303 1305 1303 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 67 72 <span type="species:ncbi:9606">women</span>
###xml 169 176 <span type="species:ncbi:4097">tobacco</span>
Our study population is unique in consisting solely of non-smoking women, who could potentially be informative with regard to risk factors that operate independently of tobacco smoking. The finding that the MDM2 TT genotype increases risk was unexpected, since as described earlier, many studies that have reported associations have found increased risk with the GG genotype that are consistent with the impact of this genotype on MDM2 RNA and protein levels, and hence, on inhibition of p53 [3]. To our knowledge, only one study has examined the combined effect of MDM2 and p53 polymorphisms and lung cancer, and this was also conducted in a Chinese population [10]. The results showed a multiplicative effect, with a 4.5-fold higher risk in those with the GG, Pro/Pro genotypes relative to TT, Arg/Arg. However, our findings suggesting that TT genotype can be a susceptibility factor are not entirely surprising, given the recent observations. Recent work using large numbers of breast cancer samples in the Chinese female population also revealed that the TT genotype predisposes to accelerated onset of cancers [26], and that the GG genotype reduced risk of leukemia [28]. Moreover, one other study has noted association of increased lung cancer risk with the TT genotype in the Chinese population [12], supporting our data. Thus, it is possible that the association of the G or the T alleles with increased cancer risk or onset age may be influenced by ethnicity and by environmental factors unique to that particular population. More in depth larger scale studies are now required to further extend these findings.
###end p 47
###begin p 48
###xml 554 559 554 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 659 664 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 848 853 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1122 1124 1122 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1459 1461 1459 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1462 1464 1462 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 907 912 <span type="species:ncbi:9606">women</span>
How does the TT genotype lead to increased cancer risk is at present not well understood, but there is evidence to suggest that the role of MDM2 in tumorigenesis may vary in a gender-specific manner, and between smokers and never smokers. Thus, it is not inconceivable that the mechanisms by which MDM2 modulates lung cancer risk can differ between populations. The role of hormones in carcinogenesis is rapidly emerging as a complex, but important pathway. Estrogen signaling, in particular the estrogen receptor (ER), is known to play a direct role in MDM2 transcription, regulating its expression [29]. The G allele of SNP309 increases the affinity of the MDM2 promoter for Sp1, a co-transcriptional activator for the estrogen receptor, and was associated with increased MDM2 expression. Consistently, Bond et. al. showed that the effect of the MDM2 polymorphism (GG) was gender-specific and enhanced in women with active estrogen signaling pathways [30]. Therefore, one would envisage that the TT genotype is associated with reduced MDM2 levels. However, MDM2 has also been shown to negatively regulate ER expression [31]. Thus, it is possible that reduced MDM2 levels expected in TT individuals could lead to elevated ER expression, and hence may elevate cancer risk - a hypothesis that requires further investigation. Given that estrogen receptors are expressed in lung tumours, particularly adenocarcinomas, and these cells are responsive to estrogen [32,33], it is possible that hormonal pathways provide an alternative mechanism by which MDM2 influences lung cancer risk in this population. Alternatively, other MDM2-dependent pathways could be modified in the TT subjects, leading to cancer susceptibility. In this respect, no studies have evaluated if specific signaling pathways are associated with the MDM2 SNPs. Given the emergence of an association of the TT genotype with cancer susceptibility in various studies, such analyses would provide further mechanistic insights.
###end p 48
###begin title 49
Conclusions
###end title 49
###begin p 50
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2 </italic>
###xml 276 281 <span type="species:ncbi:9606">women</span>
In conclusion, our findings suggest that the MDM2 SNP309 TT genotype is a risk factor for lung cancer in never-smoker Chinese females. The difference between our results and others highlights the possibility that MDM2 may operate via unique mechanisms among non-smoking Asian women.
###end p 50
###begin title 51
Competing interests
###end title 51
###begin p 52
The authors declare that they have no competing interests.
###end p 52
###begin title 53
Authors' contributions
###end title 53
###begin p 54
HWC, DN, SC, SSL and LYS carried out the molecular genetics studies. HL carried out statistical analysis. KS and AS designed the study, interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.
###end p 54
###begin title 55
Pre-publication history
###end title 55
###begin p 56
The pre-publication history for this paper can be accessed here:
###end p 56
###begin p 57

###end p 57
###begin title 58
Acknowledgements
###end title 58
###begin p 59
We thank the National Medical Research Council, Singapore (NMRC1996/0155) and the Singhealth Foundation for funding support.
###end p 59
###begin article-title 60
The p53 network in lung carcinogenesis
###end article-title 60
###begin article-title 61
Mdm2 promotes the rapid degradation of p53
###end article-title 61
###begin article-title 62
###xml 133 139 <span type="species:ncbi:9606">humans</span>
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
###end article-title 62
###begin article-title 63
A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect
###end article-title 63
###begin article-title 64
###xml 65 71 <span type="species:ncbi:10090">murine</span>
Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene
###end article-title 64
###begin article-title 65
Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk
###end article-title 65
###begin article-title 66
MDM2 SNP309 and SNP354 are not associated with lung cancer risk
###end article-title 66
###begin article-title 67
Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population
###end article-title 67
###begin article-title 68
MDM2 309T>G polymorphism and risk of lung cancer in a Korean population
###end article-title 68
###begin article-title 69
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer
###end article-title 69
###begin article-title 70
Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer
###end article-title 70
###begin article-title 71
MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis
###end article-title 71
###begin article-title 72
MDM2 SNP309 and cancer risk: a combined analysis
###end article-title 72
###begin article-title 73
Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer
###end article-title 73
###begin article-title 74
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer
###end article-title 74
###begin article-title 75
###xml 59 64 <span type="species:ncbi:9606">human</span>
Primary structure polymorphism at amino acid residue 72 of human p53
###end article-title 75
###begin article-title 76
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history
###end article-title 76
###begin article-title 77
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity
###end article-title 77
###begin article-title 78
TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis
###end article-title 78
###begin article-title 79
TP53 mutation, allelism and survival in non-small cell lung cancer
###end article-title 79
###begin article-title 80
###xml 51 59 <span type="species:ncbi:9606">patients</span>
p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis
###end article-title 80
###begin article-title 81
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism
###end article-title 81
###begin article-title 82
Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer
###end article-title 82
###begin article-title 83
Lung cancer in never smokers: a review
###end article-title 83
###begin article-title 84
Lung cancer in never smokers--a different disease
###end article-title 84
###begin article-title 85
MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population
###end article-title 85
###begin article-title 86
###xml 56 61 <span type="species:ncbi:9606">women</span>
Fumes from meat cooking and lung cancer risk in Chinese women
###end article-title 86
###begin article-title 87
###xml 99 107 <span type="species:ncbi:9606">patients</span>
MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients
###end article-title 87
###begin article-title 88
Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression
###end article-title 88
###begin article-title 89
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner
###end article-title 89
###begin article-title 90
Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents
###end article-title 90
###begin article-title 91
###xml 81 86 <span type="species:ncbi:9606">human</span>
Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers
###end article-title 91
###begin article-title 92
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen
###end article-title 92

